---
title: "RO: Sales up 6% at CER, core profit up 10% at CER, but net income down 6% in CHF due to impairments"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293561349.md"
description: "Roche Holding reported a 6% increase in sales and a 10% rise in core profit at constant exchange rates (CER) for the interim period. However, net income fell by 6% in CHF due to impairments, currency headwinds, and biosimilar competition. While free cash flow surged 58% at CER, net debt increased owing to dividend payments. Pharmaceuticals and Diagnostics segments both achieved growth at CER."
datetime: "2026-07-23T05:12:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293561349.md)
  - [en](https://longbridge.com/en/news/293561349.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293561349.md)
generator: "portal-rs"
---

# RO: Sales up 6% at CER, core profit up 10% at CER, but net income down 6% in CHF due to impairments

Group sales grew 6% at CER but declined 2% in CHF, with core operating profit up 10% at CER and core EPS up 9% at CER. Pharmaceuticals and Diagnostics both saw growth at CER, but currency headwinds and biosimilar competition weighed on reported results. Free cash flow rose 58% at CER, while net debt increased due to dividend payments.

Original document: Roche Holding Ltd \[RO\] Interim report — Jul. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Simcere Zaiming licenses SIM0660 to Roche in deal worth up to $1.53 billion](https://longbridge.com/en/news/297652647.md)
- [Roche Commits $75 Million in Blood-Cancer Deal Worth Up to $1.53 Billion](https://longbridge.com/en/news/297692233.md)
- [12:49 ETSimcere Zaiming signe un accord de licence exclusif avec Roche pour le développement mondial du SIM0660](https://longbridge.com/en/news/297813196.md)
- [04:00 ETSimcere Zaiming sluit exclusieve licentieovereenkomst met Roche voor wereldwijde ontwikkeling van SIM0660](https://longbridge.com/en/news/297751599.md)
- [BioNTech Kills a Cancer Trial Roche Helped Build](https://longbridge.com/en/news/297359309.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**